Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | Transplantation and cell therapy highlights at COSTEM 2022

Miguel-Angel Perales • 28 Oct 2022
COSTEM 2022
Acute Myeloid Leukemia Leukemia Lymphoma Multiple Myeloma CAR-T NK-Cell Therapy

Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides his highlights from the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), including debates surrounding transplantation versus CAR-Ts in myeloma and lymphoma, the role of measurable residual disease (MRD) in acute myeloid leukemia (AML), maintenance therapy in FLT3-positive AML, and developments in natural killer (NK) cells. This interview took place at COSTEM 2022 in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Miguel-Angel Perales

2:53
The utility of CD34-selected peripheral blood stem cell graft as GvHD prevention in HLA allografts
Miguel-Angel Perales • 28 Oct 2022
1:53
Prolymphocytes as a promising GvHD prophylaxis
Miguel-Angel Perales • 28 Oct 2022
1:17
The impact of CAR-T therapy in the second-line setting in lymphoma
Miguel-Angel Perales • 28 Oct 2022
6:07
Managing CRS in CAR T-cell therapy
Miguel-Angel Perales • 5 Apr 2019

Related Videos

1:49
Exciting therapeutic approaches in the AML space
Steven Knapper • 1 May 2024
4:16
The novel bioactive peptide QUB-2392 shows anti-leukemic effects in leukemia cell lines
Ruth Gyereh • 28 Apr 2024
1:15
Tackling PD1i resistance in Hodgkin lymphoma
Graham Collins • 29 Apr 2024
3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals